Barter syndrome is a rare autosomal recessive syndrome caused by a defect of chloride reabsorption in the thick ascending limb in the loop of Henle. Its antenatal variant is accompanied by polyhydranios intrauterine growth retardation and, after birth, hyponatraemic polyuric hypokalemia, alkalosis, hypercalciuria with nephrocalcinosis. It is principally underfied by the mutation of 3 genes coding for chloride channels.

**CASE REPORT 1**

MV, born 01/07/2001, Born at 30 WA, With intrauterine growth retardation (Birth weight: 1160g)

Developed at one month of life: a typical Bartter syndrome with hypercalcaemia (113 mg/L) and hyperparathyroidism (~ 200 pg/ml), hypercalciuria, stage 3 nephrocalcinosis.

Molecular genetic analysis confirmed an homozygous mutation of NKCC2 (Bartter I).

Classical treatment was undertaken, including indomethacin, water and salt supplementation, first through intravenous route and later through gastrostomy.

**Bone lesions:**

From the age of 6, stiffness of elbows, knees, ankles were noted, with an handicapping limitation of movements, without biological stigmates of inflammation nor autoimmunity.

X-ray examinations showed bone demineralization, subperiostal resorption, chronic arthropathy of the mentioned articulations (figure 1).

At DEXA, density of the femoral neck is ~ 3.6 DS.

Growth was severely impacted but difficult to measure because of joint flexum (Fig 2).

**Therapeutic attempts:**

Cinacalcet, an agonist of the Calcium Sensible Receptor, from the age of 12 at doses of 15 and then 30 mg/d: reduces parathormone levels from ~ 300 to ~100 pg/ml and calcium from ~120 to ~90 mg/L, which does not completely prevent bone resorption.

Surgical ablation of the right superior parathyroid gland, pointed out by the combination of a nodule at tomography and an increased fixation at MIBI scintigraphy after subtraction of \(^{123}\text{I}\) thyroid imaging, at the age of 12. After a partial remission, hyperparathyroidism resumed.

Growth hormone (0.3 mg/kg/d) was administered from the age of 11y \(^{10}\) during 6 months and stopped because of the absence of any effect on height.

The biphosphonate zoledronate, an antiresorptive agent, obtained a partial beneficial result on calcemia and on plasma cross-laps, markers of bone resorption (figure 3).

**CONCLUSIONS**

1) To our knowledge, only 15 cases of Bartter’s syndrome with hypercalcemia due to hyperparathyroidism have been described till yet in the literature.
2) These are the most long-lasting and severe recorded cases
3) Present hyperparathyroidism is probably linked to secondary autonomous development of a parathyroid reaction to calcium urinary leakage
4) It should be detected by a careful follow-up of calcemia in case of neonatal Bartter’s syndrome
5) The administration of cinacalcet seems to be the most efficient treatment but should be carefully monitored and titrated because of the risk of severe hypocalcaemia. The use of intravenous biphosphonates may be an option, but is not always efficient on bone resorption.

**REFERENCES**